Outcome and Immune Landscape of HER2-positive Invasive Lobular Carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial
      Google Scholar   
Citation:
J Clin Oncol vol 39 (no. 15_suppl) 535
Meeting Instance:
ASCO 2021
Year:
2021
Type:
Abstract
Sub type:
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
3906  
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
Genentech  
Grants:
U10CA180821, U24CA196171 , Susan G. Komen SAC190091, BCRF-19-161  
Corr. Author:
 
Authors:
                       
Networks:
LAPS-MN026, NY021, PR028   
Study
NCCTG-N9831
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: